Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition

被引:71
|
作者
Hu, Jinsong [1 ,2 ]
Dang, Nana [3 ]
Menu, Eline [1 ]
De Bryune, Elke [1 ]
Xu, Dehui [1 ]
Van Camp, Ben [1 ]
Van Valckenborgh, Els [1 ]
Vanderkerken, Karin [1 ]
机构
[1] Vrije Univ Brussel, Dept Hematol & Immunol, Myeloma Ctr Brussels, B-1090 Brussels, Belgium
[2] Xi An Jiao Tong Univ, Dept Genet & Mol Biol, Sch Med, Xian 710049, Peoples R China
[3] Vrije Univ Brussel, Dept Physiol Immunol, B-1090 Brussels, Belgium
关键词
UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; MULTIPLE-MYELOMA CELLS; TRANSCRIPTION FACTOR ATF5; INDUCED APOPTOSIS; ER STRESS; MITOCHONDRIAL APOPTOSIS; UP-REGULATION; BCL-2; FAMILY; KAPPA-B;
D O I
10.1182/blood-2011-07-366492
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myeloid cell leukemia-1 (Mcl-1) protein is an anti-apoptotic Bcl-2 family protein that plays essential roles in multiple myeloma (MM) survival and drug resistance. In MM, it has been demonstrated that proteasome inhibition can trigger the accumulation of Mcl-1, which has been shown to confer MM cell resistance to bortezomib-induced lethality. However, the mechanisms involved in this unwanted Mcl-1 accumulation are still unclear. The aim of the present study was to determine whether the unwanted Mcl-1 accumulation could be induced by the unfolded protein response (UPR) and to elucidate the role of the endoplasmic reticulum stress response in regulating Mcl-1 expression. Using quantitative RT-PCR and Western blot, we found that the translation of activating transcription factor-4 (ATF4), an important effector of the UPR, was also greatly enhanced by proteasome inhibition. ChIP analysis further revealed that bortezomib stimulated binding of ATF4 to a regulatory site (at position 332 to 324) at the promoter of the Mcl-1 gene. Knocking down ATF4 was paralleled by down-regulation of Mcl-1 induction by bortezomib and significantly increased bortezomib-induced apoptosis. These data identify the UPR and, more specifically, its ATF4 branch as an important mechanism mediating up-regulation of Mcl-1 by proteasome inhibition. (Blood. 2012;119(3):826-837)
引用
收藏
页码:826 / 837
页数:12
相关论文
共 50 条
  • [41] Activation of the rat cyclin a promoter by ATF2 and Jun family members and its suppression by ATF4
    Shimizu, M
    Nomura, Y
    Suzuki, K
    Ichikawa, E
    Takeuchi, A
    Suzuki, M
    Nakamura, T
    Nakajima, T
    Oda, K
    EXPERIMENTAL CELL RESEARCH, 1998, 239 (01) : 93 - 103
  • [42] Tissue Histidine Deprivation Mediates Cardiac Antioxidant Defense via Activation of GCN2-eIF2α-ATF4 Pathway
    Katayama, Takaharu
    Sano, Motoaki
    Endo, Jin
    Hayashida, Kentaro
    Fukuda, Keiichi
    CIRCULATION RESEARCH, 2008, 103 (05) : E57 - E58
  • [43] Induction of FGF21 by CO/PERK/ATF4 Pathway Mediates Metabolic Homeostasis
    Chung, Hun Taeg
    Joe, Yeonsoo
    Kim, Hyo Jeong
    Kim, Sena
    FREE RADICAL BIOLOGY AND MEDICINE, 2017, 108 : S95 - S95
  • [44] Investigating synergism of Mcl-1 inhibition with first line therapies for leukaemia
    Cosimo, E.
    Ball, R. J.
    Couves, A.
    Allan, E. K.
    Jorgensen, H. G.
    Michie, A. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 57 - 58
  • [45] MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
    Alcon, Clara
    Martin, Fernando
    Prada, Estela
    Mora, Jaume
    Soriano, Aroa
    Guillen, Gabriela
    Gallego, Soledad
    Roma, Josep
    Samitier, Josep
    Villanueva, Alberto
    Montero, Joan
    CELL DEATH DISCOVERY, 2022, 8 (01)
  • [46] Selective small molecule inhibition of anti-apoptotic MCL-1
    Cohen, Nicole A.
    Stewart, Michelle L.
    Gavathiotis, Evripidis
    Tepper, Jared L.
    Opferman, Joseph T.
    Walensky, Loren D.
    CANCER RESEARCH, 2012, 72
  • [47] MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
    Clara Alcon
    Fernando Martín
    Estela Prada
    Jaume Mora
    Aroa Soriano
    Gabriela Guillén
    Soledad Gallego
    Josep Roma
    Josep Samitier
    Alberto Villanueva
    Joan Montero
    Cell Death Discovery, 8
  • [48] Mcl-1 inhibition as a novel approach for personalized breast cancer therapy
    Bashari, M. H.
    Malvestiti, S.
    Fan, F.
    Vallet, S.
    Sattler, M.
    Cardone, M. H.
    Opferman, J. T.
    Jaeger, D.
    Podar, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 117 - 117
  • [49] Mcl-1 inhibition enhances the proapoptotic effects of vemurafenib in melanoma cells
    Sarif, Z.
    Dogan, A.
    Richtig, G.
    Fechner, H.
    Kreppel, F.
    Eberle, J.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 (03) : E106 - E106
  • [50] Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation
    Luz Flores, M.
    Castilla, Carolina
    Gasca, Jessica
    Medina, Rafael
    Perez-Valderrama, Begona
    Romero, Francisco
    Japon, Miguel A.
    Saez, Carmen
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (07) : 1713 - 1725